These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Two Different Antibody-Dependent Enhancement (ADE) Risks for SARS-CoV-2 Antibodies. Ricke DO Front Immunol; 2021; 12():640093. PubMed ID: 33717193 [TBL] [Abstract][Full Text] [Related]
4. Organisational challenges, volumes of oncological activity and patients' perception during the severe acute respiratory syndrome coronavirus 2 epidemic. Zuliani S; Zampiva I; Tregnago D; Casali M; Cavaliere A; Fumagalli A; Merler S; Riva ST; Rossi A; Zacchi F; Zaninotto E; Auriemma A; Pavarana M; Soldà C; Benini L; Borghesani M; Caldart A; Casalino S; Gaule M; Kadrija D; Mongillo M; Pesoni C; Biondani P; Cingarlini S; Fiorio E; Melisi D; Parolin V; Tondulli L; Belluomini L; Zecchetto C; Avesani B; Biasi A; Bovo C; Dazzani E; Dodi A; Gelmini S; Leta LC; Lo Cascio G; Lombardo F; Lucin E; Martinelli IA; Messineo L; Moscarda V; Pafumi S; Reni A; Sartori G; Scaglione IM; Shoval Y; Sposito M; Tacconelli E; Trestini I; Zambonin V; Zanelli S; Pilotto S; Milella M Eur J Cancer; 2020 Aug; 135():159-169. PubMed ID: 32580131 [TBL] [Abstract][Full Text] [Related]
5. Recovery from Acute SARS-CoV-2 Infection and Development of Anamnestic Immune Responses in T Cell-Depleted Rhesus Macaques. Hasenkrug KJ; Feldmann F; Myers L; Santiago ML; Guo K; Barrett BS; Mickens KL; Carmody A; Okumura A; Rao D; Collins MM; Messer RJ; Lovaglio J; Shaia C; Rosenke R; van Doremalen N; Clancy C; Saturday G; Hanley P; Smith BJ; Meade-White K; Shupert WL; Hawman DW; Feldmann H mBio; 2021 Aug; 12(4):e0150321. PubMed ID: 34311582 [TBL] [Abstract][Full Text] [Related]
6. Insight into the pediatric and adult dichotomy of COVID-19: Age-related differences in the immune response to SARS-CoV-2 infection. Fialkowski A; Gernez Y; Arya P; Weinacht KG; Kinane TB; Yonker LM Pediatr Pulmonol; 2020 Oct; 55(10):2556-2564. PubMed ID: 32710693 [TBL] [Abstract][Full Text] [Related]
7. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity. Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P Cells; 2021 Oct; 10(11):. PubMed ID: 34831172 [TBL] [Abstract][Full Text] [Related]
8. COVID-19 and autoimmune diseases. Liu Y; Sawalha AH; Lu Q Curr Opin Rheumatol; 2021 Mar; 33(2):155-162. PubMed ID: 33332890 [TBL] [Abstract][Full Text] [Related]
9. The journey of SARS-CoV-2 in human hosts: a review of immune responses, immunosuppression, and their consequences. Alshammary AF; Al-Sulaiman AM Virulence; 2021 Dec; 12(1):1771-1794. PubMed ID: 34251989 [TBL] [Abstract][Full Text] [Related]
10. Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19. Cervia C; Nilsson J; Zurbuchen Y; Valaperti A; Schreiner J; Wolfensberger A; Raeber ME; Adamo S; Weigang S; Emmenegger M; Hasler S; Bosshard PP; De Cecco E; Bächli E; Rudiger A; Stüssi-Helbling M; Huber LC; Zinkernagel AS; Schaer DJ; Aguzzi A; Kochs G; Held U; Probst-Müller E; Rampini SK; Boyman O J Allergy Clin Immunol; 2021 Feb; 147(2):545-557.e9. PubMed ID: 33221383 [TBL] [Abstract][Full Text] [Related]
11. Human Nasal and Lung Tissues Infected Alfi O; Yakirevitch A; Wald O; Wandel O; Izhar U; Oiknine-Djian E; Nevo Y; Elgavish S; Dagan E; Madgar O; Feinmesser G; Pikarsky E; Bronstein M; Vorontsov O; Jonas W; Ives J; Walter J; Zakay-Rones Z; Oberbaum M; Panet A; Wolf DG J Virol; 2021 Jun; 95(14):e0013021. PubMed ID: 33893170 [TBL] [Abstract][Full Text] [Related]
12. B cell depletion and signs of sepsis-acquired immunodeficiency in bone marrow and spleen of COVID-19 deceased. Ihlow J; Michaelis E; Greuel S; Heynol V; Lehmann A; Radbruch H; Meinhardt J; Miller F; Herbst H; Corman VM; Westermann J; Bullinger L; Horst D; von Brünneck AC; Elezkurtaj S Int J Infect Dis; 2021 Feb; 103():628-635. PubMed ID: 33401036 [TBL] [Abstract][Full Text] [Related]
13. Potent SARS-CoV-2-Specific T Cell Immunity and Low Anaphylatoxin Levels Correlate With Mild Disease Progression in COVID-19 Patients. Lafon E; Diem G; Witting C; Zaderer V; Bellmann-Weiler RM; Reindl M; Bauer A; Griesmacher A; Fux V; Hoermann G; Miller C; Zabernigg A; Wöll E; Wilflingseder D; Lass-Flörl C; Posch W Front Immunol; 2021; 12():684014. PubMed ID: 34194438 [TBL] [Abstract][Full Text] [Related]
14. SARS-CoV-2 infection as a trigger of autoimmune response. Sacchi MC; Tamiazzo S; Stobbione P; Agatea L; De Gaspari P; Stecca A; Lauritano EC; Roveta A; Tozzoli R; Guaschino R; Bonometti R Clin Transl Sci; 2021 May; 14(3):898-907. PubMed ID: 33306235 [TBL] [Abstract][Full Text] [Related]
15. Coronavirus disease 2019 and asthma, allergic rhinitis: molecular mechanisms and host-environmental interactions. Wakabayashi M; Pawankar R; Narazaki H; Ueda T; Itabashi T Curr Opin Allergy Clin Immunol; 2021 Feb; 21(1):1-7. PubMed ID: 33186186 [TBL] [Abstract][Full Text] [Related]
16. Knowledge, attitudes and practices related to the COVID-19 outbreak among Romanian adults with cancer: a cross-sectional national survey. Gheorghe AS; Negru ŞM; Nițipir C; Mazilu L; Marinca M; Gafton B; Ciuleanu TE; Schenker M; Dragomir RD; Gheorghe AD; Stovicek PO; Bandi-Vasilica M; Boț AC; Mihăilă RI; Zob DL; Kajanto AL; Stănculeanu DL ESMO Open; 2021 Feb; 6(1):100027. PubMed ID: 33399089 [TBL] [Abstract][Full Text] [Related]